주문제작 서비스 문의
찾으시는 제품이 저희 사이트에 없으신가요? 단백질 주문 제작 서비스를 이용해보세요!
주문제작 서비스 문의 >>
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 46.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
FITC-Labeled Human CD19 (20-291), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
2e5 of 293 CAR cells transfected with anti-CD19-scFv were stained with 100 μL of 10 μg/mL of FITC-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HF2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), FITC signal was used to evaluate the binding activity (QC tested).
5e5 of PBMCs were stained with FITC-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HF2H3) and anti-CD3 antibody, washed and then analyzed with FACS. PE signal was used to evaluate the expression of CD3+ T cells in PBMCs, and FITC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
가격(KRW) : 525,000
가격(KRW) : 3,600,000
ACROBiosystems는 생체 활성이 높은 균질한 CD3 δ/CD3 ε 및 CD3 γ/CD3 ε 단백질을 개발하여 이중특이 항체를 치료제로의 임상 개발을 가속시킵니다.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
오가노이드 툴 박스는 약물 개발 프로젝트의 진행을 가속할 수 있는 레디메이드 오가노이드와 오가노이드 분화 툴 키트 및 다양한 서비스를 포함하는 오가노이드 솔루션 모음입니다.
고품질 GMP 등급 사이토카인 IL-15,IL-7, IL-21 등 제품은 신속한 임상/신약승인신청을 위해 개발된 것입니다.
50+ car-t의 인기 타겟을 커버하고, car 발현 검사를 위해 특별히 설계된 항원 단백질은 스트림 검증을 통해 고특이성 car 발현을 검출할 수 있으며, 고 배치간 일관성을 가지고 있다.pe/fi표기 단백질로 한 단계 염색하면 고특이성, 무 백그라운드로 car 발현 검사를 검사할 수 있습니다.
cd20, claudin18.2, cd133, gprc5d, ccr5, ccr8을 포함한 안정적이고 활성이 높은 전장 다중 막관통 단백질은 면역, elisa, spr, bli, 세포 실험, car 양성률 검사 등에 광범위하게 사용된다. vlp, 스케일제거제, nanodisc의 다양한 기술 플랫폼은 다중 막관통 단백질을 목표로 하는 약물 연구에 도움을 준다.
GMP 등급 사이토카인. 고품질 세포 활성화 및 확장 시약. 유전자 편집 시약, 효소 CAR 검사 시약 등 제품. 세포 및 유전자 요법 고객님에게 포괄적인 솔루션을 제공하고 초기 약물 발견에서 임상 연구에 이르기까지 모든 단계에서 귀하와 동반하겠습니다.
현재 이미 알려진 거의 대부분의 면역 체크 포인트 분자를 포함하여 다양한 레벨과 물종을 제공하여 고객이 선택할수 있도록 하고있다. 천연중합체 형식은 mals를 통해 검증되었고 생물활성은 elisa/spr/bli/facs 등을 통해 검증되었으며 또한 biotin/fitc 표지는 높은 처리량을 가진 항체를 선별하는데 편리하다.
ACROBiosystems는 ADC약물의 연구개발을 돕기 위해 노력하고 있으며, 다양한 인기 타겟에 서로 다른 종, 다른 라벨의 제품을 개발했으며, 높은 순도, 높은 친화력 등 특징을 가지고 있으며, 면역, 항체 선택, spr, 세포 활성 검사 및 기타 실험에 적합하고, 해당 protocol을 무료로 제공합니다.
Fc 수용체 단백질은 모든 분자를 포함하고 있을 뿐만 아니라, 일반적인 돌연변이와 바이오틴 표기 종류을 포함하고 있어 고객들이 단일 클론 항체 개발을 가속화할 수 있다.
포괄적으로 풍부한 사이토카인 표적 단백질은 HEK293 진핵생물 시스템에 의해 발현되며 천연 구조에 더 가깝다. 고순도는 SDS-PAGE/HPLC/MALS에 의해 검증된다. 높은 생물학적 활성이 ELISA/SPR/BLI에 의해 검증된다. 배치간 일관성이 우수하여 항체 면역, 스크리닝 및 품질 관리 과정에 적합하다.
Aneuro는 ACROBiosystems가 뇌과학 연구에 초점을 맞춘 제품 라인으로서 치료 및 진단 연구 단백질, PFFs와 재조합 신경 인자 등 뇌과학 연구 분야에 중요한 단백질 제품을 제공하여 뇌과학 연구에 도움이 된다.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tafasitamab | MOR-00208; XmAb-5574; MOR-208; XENP-5574 | Approved | Xencor Inc | MONJUVI, Minjuvi | United States | Lymphoma, Large B-Cell, Diffuse | Morphosys Us Inc | 2020-07-31 | Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Hemic and Lymphatic Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Tisagenlecleucel | LG-740; CART-019; CTL-019; CART-19 | Approved | Novartis Pharma Ag, University Of Pennsylvania | Kymriah | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Novartis Pharmaceuticals Corp | 2017-08-30 | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Central Nervous System Lymphoma | Details |
Axicabtagene ciloleucel | FKC-876; KTE-C19; KTE C19 | Approved | Cabaret Biotech | Yescarta, 奕凯达 | United States | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, B-Cell | Kite Pharma Eu Bv | 2017-10-18 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Inaticabtagene Autoleucel | CNCT19; CNCT-19; HY001 | Approved | Juventas Cell Therapy Ltd | 源瑞达 | Mainland China | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Juventas Cell Therapy Ltd | 2023-11-08 | Hematologic Neoplasms; Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Inebilizumab | MT-0551; VIB-0551; 16C4-aFuc; MEDI-551 | Approved | Duke University, Horizon Therapeutics PLC | Uplizna, ユプリズナ, Uplinza, 昕越 | United States | Neuromyelitis Optica | Viela Bio Inc | 2020-06-11 | Hematologic Neoplasms; Lymphoma, B-Cell; Rejection of renal transplantation; Myasthenia Gravis; Immunoglobulin G4-Related Disease; Scleroderma, Systemic; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, B-Cell; Encephalitis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Relmacabtagene autoleucel | JWCAR-029 | Approved | Jw Therapeutics (Shanghai) Co Ltd | 倍诺达, Carteyva | Mainland China | Lymphoma, Large B-Cell, Diffuse | Jw Therapeutics (Shanghai) Co Ltd | 2021-09-01 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Loncastuximab tesirine | MT-2111; ADCT-402 | Approved | Adc Therapeutics Sa | ZYNLONTA, Lonca | United States | Lymphoma, Large B-Cell, Diffuse | Adc Therapeutics Sa | 2021-04-23 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Actalycabtagene autoleucel | NexCAR19; HCAR19 | Approved | ImmunoACT Ltd | India | Leukemia | ImmunoACT Ltd | 2023-10-13 | Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Blinatumomab | BiTE-MT-103; bscCD19xCD3; AMG-103; MT-103; MEDI-538 | Approved | Micromet Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Leukemia; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Brexucabtagene autoleucel | KTE-X19; FKC-889 | Approved | Tecartus | United States | Lymphoma, Mantle-Cell | Kite Pharma Inc | 2020-07-24 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Lisocabtagene maraleucel | Liso-Cel; JCAR-017; JCAR017; BMS-986387 | Approved | Juno Therapeutics Inc | Breyanzi | United States | Lymphoma, Large B-Cell, Diffuse | Bristol-Myers Squibb Company | 2021-02-05 | Lymphoma, B-Cell; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Mediastinal Neoplasms; Immune System Diseases; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) | Phase 3 Clinical | Chaim Sheba Medical Center At Tel Hashomer | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
Anti-CD19 CAR T-cell therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Lymphoma, B-Cell | Details | |
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) | Phase 3 Clinical | Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic | Details |
CD19 CAR-T cell therapy (National University of Malaysia) | Phase 3 Clinical | National University Of Malaysia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
CAR-T 19 cell therapy (University of Pennsylvania) | Phase 2 Clinical | University Of Pennsylvania | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CLIC-1901 (Ottawa Hospital Research Institute) | CLIC-1901 | Phase 2 Clinical | Ottawa Hospital Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
AUTO-3 | AUTO-3 | Phase 2 Clinical | University College London | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
GC-007g | GC007g; GC-007g | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma | Details | |
Evoncabtagene pazurgedleucel | CTX-110 | Phase 2 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19 CAR-T cell therapy (Chongqing Precision Biotech) | MC-1-50 | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Dermatomyositis; Lymphoma, Large B-Cell, Diffuse; Sjogren's Syndrome; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) | Phase 2 Clinical | Shanghai Zhongshan Hospital, Hrain Biotechnology Co Ltd | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular | Details | |
BZ019 | BZ-019 | Phase 2 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma | Details |
TAK-007 | TAK-007 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, Non-Hodgkin | Details |
CART-19 cells (Henan Hualong Biotechnology) | Phase 2 Clinical | Henan Hualong Biotechnology | Leukemia, Lymphoid | Details | |
pCAR-19B | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) | ORGCAR19; ORGCAR-19 | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Lymphoma, B-Cell; Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-19 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene) | BG-19; BG-19C; BG-T19 | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
GC-022 | GC-022; GC-022F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 2 Clinical | The First Affiliated Hospital Of Nanchang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CAR-CD19 T cell therapy | Phase 2 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) | XLCART-001 | Phase 2 Clinical | Nanjing Medical University | Lymphoma, B-Cell | Details |
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) | Phase 2 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
IM19 chimeric antigen receptor T cell therapy | IM19 | Phase 2 Clinical | Beijing Yimiao Medical Technology Co Ltd | Leukemia; Hematologic Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma | Details |
CD19.CAR T Cells (Heidelberg University Hospital) | Phase 2 Clinical | Heidelberg University Hospital | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) | Phase 2 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Diseases; Lymphoma, B-Cell | Details | |
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University, Suzhou University | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) | Phase 2 Clinical | University Of Alberta | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
GC-012F | GC-012F; GC012F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) | CARCIK-CD19; CIK-CAR.CD19 | Phase 2 Clinical | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
TC-110 | TC-110 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
3rd-gen-CD19-CAR | 3rd-gen-CD19-CAR | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
HuCART19 | Phase 2 Clinical | National Cancer Institute | Lymphoma, B-Cell; Rejection of renal transplantation; Renal Insufficiency; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic | Details | |
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital | Leukemia | Details | |
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) | ssCART-19 | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
CD19 chimeric antigen receptor T cell therapy (Takara Bio) | TBI-1501 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Takara Bio Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Rapcabtagene autoleucel | YTB-323 | Phase 2 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) | SENL-B19 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia; Lymphoma, B-Cell; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
KQ-2003 | KQ2003; KQ-2003 | Phase 2 Clinical | Shanghai Keqi Pharmaceutical Technology Co Ltd | Solid tumours; Multiple Myeloma; POEMS Syndrome | Details |
C-CAR011 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
ALLO-501 | ALLO-501 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Azercabtagene zapreleucel | PBCAR-0191 | Phase 2 Clinical | Baxalta Incorporated | Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin | Details |
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic | Details | |
BinD-19 (Shenzhen BinDeBio) | BinD-19 | Phase 2 Clinical | Shenzhen Bindebio Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
U-CART (Shanghai Bioray Laboratory Inc) | Phase 2 Clinical | BRL Medicine Inc | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Central Nervous System Lymphoma | Details | |
CD19 Universal CAR-γδ T Cells Therapy(Guangzhou Bio-Gene Technology) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) | Phase 2 Clinical | Beijing Tongren Hospital, Cmu | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
IMPT-514 | IMPT-514 | Phase 2 Clinical | ImmPACT Bio USA Inc | Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
Anti-CD19 Autologous CAR-T Cell therapy (920th Hospital) | OlyCAR-019 | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-CD19 CAR-T cells with TNFRS19 transmembrane domain | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
AT-101 (AbClon) | AT-101 | Phase 2 Clinical | Abclon Inc | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details |
CABA-201 | CABA-201 | Phase 2 Clinical | Cabaletta Bio Inc | Myasthenia Gravis; Myositis; Dermatomyositis; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic; Muscular Diseases | Details |
EB-103 | EB-103 | Phase 2 Clinical | Estrella Biopharma Inc, Eureka Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, AIDS-Related; Lymphoma; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details |
Anti-CD19 CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Lymphoma, Non-Hodgkin | Details | |
CD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina) | Phase 2 Clinical | Medical University Of South Carolina | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Denocabtagene Ciloleucel(Beijing Yongtai Ruike Biotechnology Company) | RC19D2; CAR-T-19-D2; RC19-D2; CAR-T-19-DNR | Phase 2 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 UCAR-NK cells(920th Hospital of Joint Logistics Support Force of People's Liberation Army of China) | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
BCN-CP01 | BCN-CP01; BCN CP01; BCN-CP-01; GLPG5201; GLPG-5201 | Phase 2 Clinical | CellPoint BV | Leukemia, Lymphocytic, Chronic, B-Cell | Details |
GLPG-5101 | 19-CP-02; GLPG5101; 19CP02 | Phase 2 Clinical | CellPoint BV | Lymphoma, Non-Hodgkin | Details |
Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, Non-Hodgkin | Details | |
BRL-201 | BRL-201; PD1-19bbz; PD1-19bbz CAR-T | Phase 2 Clinical | BRL Medicine Inc | Leukemia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) | PL-001 | Phase 2 Clinical | Pell Bio-Med Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Emfizatamab | GNC-038 | Phase 2 Clinical | SystImmune | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma | Details |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
ISIKOK-19 | ISIKOK-19 | Phase 2 Clinical | Acibadem University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Candidiasis, Vulvovaginal; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous anti-CD19 CAR T cell therapy(Kyverna Therapeutics) | KYV-101 | Phase 2 Clinical | National Institutes Of Health, Kyverna Therapeutics Inc | Myasthenia Gravis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Dermatomyositis; Multiple Sclerosis; Lupus Nephritis; Multiple Sclerosis, Chronic Progressive; Scleroderma, Diffuse | Details |
ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Bispecific CD19/22 CAR T cells | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Lymphoma; Lymphoma, Non-Hodgkin | Details | |
UCART019 | UCART-019 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
NCAR19-T | Phase 2 Clinical | Second Military Medical University Of Chinese People'S Liberation Army | Lymphoma, B-Cell | Details | |
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
19273-4SCAR | 19273-4SCAR | Phase 2 Clinical | Peking University | Lymphoma, B-Cell | Details |
Allogeneic CD-19 CAR-T Cell Therapy | Phase 2 Clinical | Shenzhen University General Hospital | Leukemia; Lymphoma, B-Cell | Details | |
CAR-T-19(Immunotech Biopharm) | CAR-T-19(Immunotech Biopharm) | Phase 2 Clinical | Immunotech Biopharm Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ThisCART-19 | ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B | Phase 2 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Anemia, Hemolytic, Autoimmune; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma | Details |
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Anbalcabtagene autoleucel | CRC-01 | Phase 2 Clinical | Curocell Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Details |
CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Varnimcabtagene autoleucel | ARI-0001; IMN-003A; IMN-003-A | Phase 2 Clinical | Hospital Clínic De Barcelona, Institut D'Investigacions Biomèdiques August Pi I Sunyer | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma | Details | |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 2 Clinical | Shanghai Ultra-T Immune Therapeutics Co LTD | Leukemia, B-Cell | Details | |
Prizloncabtagene autoleucel | C-CAR039; C-CAR-039; C CAR 039; EXP-039 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Budoprutug | Phase 2 Clinical | ValenzaBio Inc | Glomerulonephritis, Membranous; Nephrosis, Lipoid; Glomerulosclerosis, Focal Segmental | Details | |
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) | Phase 2 Clinical | Nanfang Hospital Of Southern Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute | Details | |
GC019F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
AZD-0486 | TNB-486; AZD-0486; AZD0486 | Phase 2 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) | Phase 2 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CN-201 | CN-201 | Phase 2 Clinical | Curon Biopharmaceutical Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Candidiasis, Vulvovaginal; Neoplasm, Residual; Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Uppsala University) | Phase 2 Clinical | Uppsala University | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) | Phase 2 Clinical | Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University | Lymphoma, B-Cell; Myasthenia Gravis; Lymphoma, Large B-Cell, Diffuse; Neuromyelitis Optica; Leukemia, B-Cell; Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) | yinnuokati-19 | Phase 2 Clinical | Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) | BPX-401 | Phase 2 Clinical | Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19 CAR-T (HuaDao CAR-Tcell) | Phase 2 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
JCAR-014 | JCAR-014; JCAR021 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc | Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
CD19.CAR-VST | CD19.CAR-VST | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
TI-1007 | TI-1007 | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Lymphoma, B-Cell | Details |
ET019003-T Cells | ET-019003 | Phase 1 Clinical | Wuhan Union Hospital, Eureka Therapeutics Inc | Leukemia; Lymphoma | Details |
PCAR-019 (Anke Biotechnology) | Phase 1 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) | Phase 1 Clinical | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
PTG-01 | PTG-01 | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Candidiasis, Vulvovaginal; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome | Details | |
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) | WZTL002-1 | Phase 1 Clinical | The Malaghan Institute Of Medical Research | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 1 Clinical | Dehe Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd | Lymphoma, B-Cell; Glioblastoma | Details | |
H-31970-SAGAN | H-31970-SAGAN | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
Zeripatamig | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Leukemia; Lymphoma, Non-Hodgkin | Details | |
Autologous CD19 CAR+ EGFTt + T cells (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Leukemia, B-Cell | Details | |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19-Car T Cell Therapy(City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) | Phase 1 Clinical | Nagoya University, Shinshu University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
XYF19 CAR-T Cell Therapy | XYF-19 | Phase 1 Clinical | Guangzhou Yinming Biomedical Technology Co Ltd, Xi'An Yufan Biotechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Vadacabtagene leraleucel | 19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells | Phase 1 Clinical | Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) | Phase 1 Clinical | Juno Therapeutics Inc | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
KD-019 (Nanjing KAEDI Biotech) | KD-C19 (Nanjing KAEDI Biotech) | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Leukemia; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
Humanized CD19 CAR-T cell therapy (Yake) | YK-C19 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 CAR T-cell therapy (University College London) | 4G7-CARD | Phase 1 Clinical | University College London | Central Nervous System Lymphoma | Details |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
ICT19G1 | ICT-19G1 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
ET-019002 | ET-019002 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
MC-19PD1 CAR-T cell therapy (Peking University) | Phase 1 Clinical | Peking University | Lymphoma | Details | |
CC-97540 | CC-97540; BMS-986353 | Phase 1 Clinical | Juno Therapeutics Inc | Myositis; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Multiple Sclerosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma | Details |
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia | Details | |
Virus-specific-CD19.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19-CD34 CAR transduced T cell therapy (Loyola University) | Phase 1 Clinical | Loyola University Chicago | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) | Phase 1 Clinical | Aikangd Biomedical Technology (Suzhou) Co Ltd | Leukemia; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Senl-1904A | Senl-1904A; Senl_1904A | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
aCD19z | aCD19z | Phase 1 Clinical | Christie Hospital Nhs Foundation Trust | Lymphoma, Non-Hodgkin | Details |
CD19-STAR-T cell therapy (China Immunotech Co Ltd) | Phase 1 Clinical | Hebei Yanda Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) | Phase 1 Clinical | Kunming Medical University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
GC-007F (Gracell Biotechnology) | GC-007F | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CAR(The University Of Texas MD Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia; Lymphoma | Details | |
B-019 | B-019 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
KT-030 | KT-030 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
UCART-19 | S-68587; UCART-19 | Phase 1 Clinical | Cellectis Sa | Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Dual CD19/CD20 targeting CAR-T therapy(Poseida Therapeutics) | Phase 1 Clinical | Poseida Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19-CART (Unicar-Therapy Bio-medicine Technology) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy(TriArm Therapeutics) | Phase 1 Clinical | TriArm Therapeutics (Shanghai) Co Ltd | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
CD19-t-haNK | Phase 1 Clinical | Nantkwest Inc, Immunitybio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Large-Cell, Anaplastic | Details | |
OnCARlytics(Imugene) | CF-33-CD-19 | Phase 1 Clinical | City Of Hope National Medical Center, Imugene Ltd | Solid tumours | Details |
KITE-363 | KITE-363 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details | |
SYNCAR-001 | SYNCAR-001 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ATA-3219 | ATA-3219; ATA3219 | Phase 1 Clinical | Atara Biotherapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lymphoma, Non-Hodgkin; Lymphoma | Details |
CLN-978 | CLN-978 | Phase 1 Clinical | Adimab LLC | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
SC-291 | SC-291; SC291 | Phase 1 Clinical | Sana Biotechnology Inc | Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Lupus Erythematosus, Cutaneous; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid; Central Nervous System Lymphoma | Details | |
LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
EGFRt/19-28z/IL-12 CAR T Cells therapy(Roswell Park Cancer Institute) | Phase 1 Clinical | Roswell Park Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
SC-U02 | nvGT UCART19; SC-U02 | Phase 1 Clinical | Sunnycell Therapeutics Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) | FKC-288; FKC288 | Phase 1 Clinical | Nanjing University School Of Medicine | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Nephritis | Details |
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lymphoma, B-Cell; Autoimmune Diseases | Details | |
AUTO-1-NG | AUTO-1-NG; AUTO1/22 | Phase 1 Clinical | Autolus Therapeutics Plc, University College London | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details |
Allogeneic Second-generation CD19-CAR T Cells therapy(Bambino Gesu Hospital And Research Institute) | Phase 1 Clinical | Bambino Gesu Hospital And Research Institute | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4SCAR19U T Cells Therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR19U cells | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
UTAA-09 | UTAA 09/17; UTAA-09; UTAA09; UTAA09/17γδT | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Lymphoma, B-Cell | Details |
QH-103 Cell Therapy | QH-103 | Phase 1 Clinical | Anhui Provincial Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
TBI-2001 | TBI-2001 | Phase 1 Clinical | University Health Network, Takara Bio Inc | Lymphoma, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
PBCAR19B | PBCAR-19B | Phase 1 Clinical | Baxalta Incorporated, Precision Biosciences Inc | Hematologic Neoplasms; Neoplasms | Details |
IASO-782 | IASO-782; IASO782 | Phase 1 Clinical | Shanghai Xunlu Biotechnology Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Anemia, Hemolytic, Autoimmune; Thrombocytopenia; Anemia, Hemolytic | Details |
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19 specific Chimeric Antigen Receptor T Cell therapy(Nationwide Children'S Hospital) | Phase 1 Clinical | Nationwide Children'S Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) | SWK001; SWK-001 | Phase 1 Clinical | Hunan Siweikang Pharmaceutical Co Ltd | Multiple Myeloma | Details |
Metabolically Armed CD19 CAR-T cells(Leman Biotech) | Meta10-19 | Phase 1 Clinical | Leman Biotech Co Ltd, Anhui Provincial Hospital | Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CARTHIAE-1 | CARTHIAE-1 | Phase 1 Clinical | Miltenyi Biotec Inc, Hospital Israelita Albert Einstein | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD19-7×19 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Human CD19 Targeted DASH CAR-T Cells (Hrain Biotechnology) | HR016 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19-CAR-NK(JD Biotech) | JD-010; JD010 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Hematologic Neoplasms | Details |
Anti-CD19-CAR T cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia | Details | |
Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Leukemia; Lymphoma | Details | |
CAR-DC(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
CD19-CAR-T cell therapy (China Immunotech/Avalon Globocare) | AVA-001 (Avalon GloboCare); AVA-001 | Phase 1 Clinical | Avalon Globocare Corp | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19 directed CAR T cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
U-01 | U-01 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, B-Cell | Details |
ABBV-319 | ABBV-319 | Phase 1 Clinical | Abbvie Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) | RJMty-19 | Phase 1 Clinical | Zhejiang Ruijiamei Biotechnologies Co Ltd | Lymphoma, B-Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Scleroderma, Systemic; Autoimmune Diseases; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
SNC-103 | SNC-103; SNC103; F01; F-01 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Leukemia, Myeloid, Acute | Details |
QN-019a | QN-019a | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Anti-CD19 universal chimeric antigen receptor T cell therapy (BRL Medicine) | BRL-301; CD19-UCART | Phase 1 Clinical | BRL Medicine Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) | Phase 1 Clinical | Pla General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) | Phase 1 Clinical | Zhejiang University, Ningbo Yake Biotechnology Co Ltd | Lymphoma | Details | |
RG-6333 | RO-7443904 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Lymphoma, Non-Hodgkin | Details |
SNUH-CD19-CAR-T Cell Therapy | SNUH-CD19-CAR-T | Phase 1 Clinical | Seoul National University Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
YK-012 | YK012 | Phase 1 Clinical | Lymphoma, B-Cell | Details | |
KUR-502 CD19 CAR-NKT | CMD-502; KUR-502 | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CNTY-101 | CNTY-101 | Phase 1 Clinical | Century Therapeutics Llc | Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
aT19 (Beijing Yongtai Ruike Biotechnology) | aT19; aT-19 | Phase 1 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
GC-502 | GC-502 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Lymphoma, Non-Hodgkin | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Autologous CAR19 T lymphocytes Therapy | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
Englumafusp alfa | RG-6076; RO-7227166 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, Non-Hodgkin | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CAR-iNKT cells therapy (North Jiangsu People's Hospital) | Phase 1 Clinical | Affiliated Hospital Of Jiangsu University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma | Details | |
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) | Phase 1 Clinical | Sabz Biomedicals | Leukemia, Biphenotypic, Acute | Details | |
Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
NKX-019 | NKX-019 | Phase 1 Clinical | Nkarta Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
IKS-03 | LCB 73; IKS 03; IKS-03; NI-2201 | Phase 1 Clinical | Legochem Biosciences Inc, Novimmune Sa | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
CTA-30X | CTA-30X; CTA30X | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
huCART19-IL18 | Phase 1 Clinical | University Of Pennsylvania | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CB-010 | CB-010 | Phase 1 Clinical | Caribou Biosciences Inc | Lymphoma, B-Cell; Lupus Nephritis; Lymphoma; Lymphoma, Non-Hodgkin | Details |
FT-819 | FT-8198; FT-819; FT 8198 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
HY-004 (Juventas) | HY-004 (Juventas) | Phase 1 Clinical | Juventas Cell Therapy Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Anti-human CD19-CD22 T cell therapy | HR004 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma | Details |
PBLTT52CAR19 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Murine CD19 CAR-T cell therapy (Yake) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells | TAK-940 | Phase 1 Clinical | Takeda, Memorial Sloan Kettering Cancer Center | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) | Phase 1 Clinical | Hebei Yanda Ludaopei Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
GB5005 chimeric antigen receptor T cell therapy (Genbase) | GB-5005 | Phase 1 Clinical | Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd | Leukemia, B-Cell | Details |
ET190L1-ARTEMIS T cells (Eureka Therapeutics) | ET190L1-ARTEMI; ET-190; ET190L1; ET190 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CLBR-001/SWI-019 | CLBR-001/SWI-019 | Phase 1 Clinical | Abbvie Inc, California Institute For Biomedical Research | Lymphoma, B-Cell | Details |
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ET-02 | ET-02 | Clinical | Edigene Inc | Lymphoma, B-Cell | Details |
PD-1Ab21-CD19CAR-T (CD biopharma) | CD-202; PZ04 | Clinical | Hematologic Neoplasms | Details | |
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) | PZ-01 | Clinical | Pinze Lifetechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
B6I-28Z CAR T cell therapy (The Affiliated Hospital of Xuzhou Medical University) | Clinical | The Affiliated Hospital Of Xuzhou Medical University | Lymphoma, B-Cell | Details | |
BCM-5011 | BCM-5011 | Clinical | ImmuneCyte Inc | Lymphoma, B-Cell | Details |
Anti-CD19 CAR-T Cells (Shaanxi Provincial People'S Hospital) | Clinical | Shaanxi Provincial People'S Hospital | Leukemia, B-Cell | Details | |
4G7SDIE | Clinical | Synimmune Gmbh, University Of Tubingen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) | Clinical | Leidos | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy(Chinese PLA General Hospital) | The Seventh Medical Center Of Chinese Pla General Hospital | Details | |||
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | The Second People Hospital Of Guangdong Province | Details | |||
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details | |||
Anti-CD19 CAR NK Cell therapy (Enricnk) | KN5501; KN-5501 | Nanjing Enricnk Biotech Co Ltd | Details | ||
Cemacabtagene ansegedleucel (Allogene Therapeutics) | ALLO-501A; ALLO-501.1 | Cellectis Sa | Details |
This web search service is supported by Google Inc.